BSC-1 非洲绿猴肾细胞
Catalogue No.: C272
Product Format: a T25 flask
Culture Properties：贴壁
Complete Growth Medium: 89%EMEM(MEM+NEAA)+10%FBS+1%双抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application:  Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components  

(pembrolizumab)  showed  limited  antitumor activity with  an  objective  response  rate  (ORR)  of  3.7%  in  107 patients with advanced well-differentiated neuroendocrine tumors (NET)  (6).  The  multicohort,  phase  1  KEYNOTE-028 study  in patients with  PD-L1-positive  NET treated with pembrolizumab demonstrated an ORR of 12.0% inpatients with carcinoid and 6.3% in  patients  with  well-differentiated  or  moderately-differentiated pancreatic NET (7). In addition, based on a phase II basket trial of anti-CTLA-4  (ipilimumab)  and  anti-PD-1  (nivolumab)